drugset / Trial / NCT02588586
A Study of the Safety and Antiretroviral Activity of 3BNC117
Phase 2
Completed
17 enrolled
Rockefeller University
Bill and Melinda Gates Foundation · collabMontefiore Medical Center · collabNational Institute of Allergy and Infectious Diseases (NIAID) · collabWeill Medical College of Cornell University · collab
NaSingle-groupOpen-labelTreatment
Summary
This study evaluates the effects of four infusions of 3BNC117 in preventing or delaying rebound of viral load during a brief treatment interruption of standard ART, and its safety during a brief analytical interruption of antiretroviral therapy.
Timeline
- Start
- 2015-10
- Primary completion
- 2018-02
- Completion
- 2018-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LAFUVITUG | Monoclonal antibody | 30 mg/kg | Intravenous |